THERMO FISHER SCIENTIFIC INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
TMO$718.20-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31,
| December 31, | December 31, | |
|---|---|---|
| (In millions except share and per share amounts) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $9,852 | $4,009 |
| Short-term investments | 253 | 1,561 |
| Accounts receivable, less allowances of $147 and $173 | 8,900 | 8,191 |
| Inventories | 5,425 | 4,978 |
| Contract assets, net | 1,666 | 1,435 |
| Other current assets | 2,612 | 1,964 |
| Total current assets | 28,707 | 22,137 |
| Property, plant and equipment, net | 10,565 | 9,306 |
| Acquisition-related intangible assets, net | 15,838 | 15,533 |
| Other assets | 5,871 | 4,492 |
| Goodwill | 49,362 | 45,853 |
| Total assets | $110,343 | $97,321 |
| Liabilities, redeemable noncontrolling interest and equity | ||
| Current liabilities: | ||
| Short-term obligations and current maturities of long-term obligations | $3,533 | $2,214 |
| Accounts payable | 3,622 | 3,079 |
| Accrued payroll and employee benefits | 1,995 | 1,988 |
| Contract liabilities | 2,710 | 2,852 |
| Other accrued expenses | 3,329 | 3,199 |
| Total current liabilities | 15,189 | 13,332 |
| Deferred income taxes | 1,493 | 1,268 |
| Other long-term liabilities | 4,273 | 3,989 |
| Long-term obligations | 35,852 | 29,061 |
| Commitments and contingencies (Note 5) | ||
| Redeemable noncontrolling interest | 122 | 120 |
| Equity: | ||
| Thermo Fisher Scientific Inc. shareholders’ equity: | ||
| Preferred stock, $100 par value, 50,000 shares authorized; none issued | — | — |
| Common stock, $1 par value, 1,200,000,000 shares authorized; 445,160,301 and 443,841,240 shares issued | 445 | 444 |
| Capital in excess of par value | 18,563 | 17,962 |
| Retained earnings | 59,156 | 53,102 |
| Treasury stock at cost, 68,938,831 and 63,066,906 shares | (22,309) | (19,226) |
| Accumulated other comprehensive income/(loss) | (2,448) | (2,697) |
| Total Thermo Fisher Scientific Inc. shareholders’ equity | 53,407 | 49,584 |
| Noncontrolling interests | 7 | (33) |
| Total equity | 53,415 | 49,551 |
| Total liabilities, redeemable noncontrolling interest and equity | $110,343 | $97,321 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.